XTX Topco Ltd Invests $457,000 in Cogent Biosciences, Inc. (NASDAQ:COGT)

XTX Topco Ltd purchased a new position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 58,560 shares of the technology company's stock, valued at approximately $457,000. XTX Topco Ltd owned 0.05% of Cogent Biosciences as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in the company. FMR LLC grew its position in shares of Cogent Biosciences by 99.2% in the fourth quarter. FMR LLC now owns 16,569,256 shares of the technology company's stock valued at $129,240,000 after purchasing an additional 8,249,845 shares in the last quarter. Vanguard Group Inc. grew its holdings in Cogent Biosciences by 7.3% during the 4th quarter. Vanguard Group Inc. now owns 6,133,380 shares of the technology company's stock valued at $47,840,000 after buying an additional 418,975 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Cogent Biosciences by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 2,308,509 shares of the technology company's stock valued at $18,011,000 after buying an additional 27,716 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Cogent Biosciences by 28.3% in the fourth quarter. Franklin Resources Inc. now owns 1,283,673 shares of the technology company's stock worth $10,013,000 after buying an additional 283,506 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of Cogent Biosciences by 2,865.3% in the fourth quarter. SG Americas Securities LLC now owns 964,712 shares of the technology company's stock valued at $7,525,000 after acquiring an additional 932,179 shares during the period.

Cogent Biosciences Price Performance

NASDAQ COGT traded up $0.04 during trading on Thursday, hitting $4.51. 902,577 shares of the company's stock traded hands, compared to its average volume of 1,262,122. The stock has a fifty day moving average of $6.24 and a two-hundred day moving average of $8.29. Cogent Biosciences, Inc. has a 12-month low of $3.72 and a 12-month high of $12.61. The firm has a market cap of $513.46 million, a P/E ratio of -1.82 and a beta of 1.67.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on COGT shares. Robert W. Baird decreased their target price on shares of Cogent Biosciences from $10.00 to $8.00 and set a "neutral" rating on the stock in a report on Thursday, February 27th. Piper Sandler upgraded Cogent Biosciences to a "strong-buy" rating in a research report on Friday, March 7th. Wedbush restated a "neutral" rating and set a $11.00 target price on shares of Cogent Biosciences in a research report on Tuesday, February 25th. HC Wainwright lowered their price target on Cogent Biosciences from $17.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday, January 14th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Cogent Biosciences in a report on Wednesday, February 26th. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $14.43.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.